PEXEGRA DIN 02553945
Status: Marketed
Holder: JAMP PHARMA CORPORATION
Health Canada record
| Active ingredient(s) | PEGFILGRASTIM 10 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | L03AA13 PEGFILGRASTIM |
|---|
| Original market date | 09-Sep-2025 |
|---|
| Current status date | 09-Sep-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PEGFILGRASTIM
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02550857 | ARMLUPEG | LUPIN PHARMA CANADA LIMITED | Solution | PEGFILGRASTIM 6 MG | Approved |
| 02564394 | DYRUPEG | CURATEQ BIOLOGICS PRIVATE LIMITED | Solution | PEGFILGRASTIM 6 MG | Approved |
| 02484153 | FULPHILA | BIOCON BIOLOGICS CANADA INC | Solution | PEGFILGRASTIM 10 MG | Marketed |
| 02529343 | LAPELGA | APOTEX INC | Solution | PEGFILGRASTIM 6 MG | Marketed |
| 02474565 | LAPELGA | APOTEX INC | Solution | PEGFILGRASTIM 6 MG | Marketed |
| 02249790 | NEULASTA | AMGEN CANADA INC | Solution | PEGFILGRASTIM 10 MG | Marketed |
| 02546973 | NIOPEG | NORA PHARMA INC | Solution | PEGFILGRASTIM 6 MG | Marketed |
| 02506238 | NYVEPRIA | PFIZER CANADA ULC | Solution | PEGFILGRASTIM 6 MG | Marketed |
| 02497395 | ZIEXTENZO | SANDOZ CANADA INCORPORATED | Solution | PEGFILGRASTIM 6 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 34568 | 2024-12-13 | New Drug Submission (NDS) | |
Request a quote for PEXEGRA
How to read a Canadian DIN record